Conference Reports for NATAP

Back

4th IAS (Intl AIDS Society) Conference on HIV Pathogenesis, Treatment and Prevention Sydney, Australia 22-25 July 2007     Relationships between markers of immunodeficiency and non AIDS related causes of death in cART era, CASCADE Study Group (09/07/06)   SMART Yields More Reasons To Shun Drug Breaks (08/21/06)   Baseline CD4 Cell Count and Immune Reconstitution During Combination Antiretroviral Therapy in ACTG 384 (08/16/06)   Major clinical outcomes in patients not treated with antiretroviral therapy (ART) at baseline in SMART; A rationale for a trial to examine early treatment of HIV disease - (08/10/06)   Initiation of Antiretroviral Therapy at CD4+ Cell Counts ≥350 cells/mm3 Does Not Increase Incidence or Risk of Peripheral Neuropathy, Anemia, or Renal Insufficiency in the HIV Outpatient (HOPS) Cohort - (08/10/06)   A CD4 threshold below 350 cells/mm3 for initiation of HAART is associated with a higher risk of AIDS, ATHENA Cohort - (08/10/06)   Hepatitis C Viral Kinetics During Treatment With Weekly Versus Twice Weekly Peg IFN-alpha-2a in HIV/HCV Co-infected Patients - (08/10/06)   Once-Daily Abacavir/Lamivudine (ABC/3TC) and Boosted Atazanavir (ATV/r): 48-Week Analysis from COL102060 (SHARE) - (08/10/06)   An Open-Label, Two-Period, Crossover, PK Study of Abacavir (ABC) and Its Intracellular Anabolite Carbovir Triphosphate (CBV-TP) Following 600mg Once-Daily and 300mg Twice-Daily Administration of Abacavir in HIV-Infected Subjects - (08/10/06)   New Data on Gains From Starting Antiretrovirals Earlier - Written by Mark Mascolini - (08/10/06)   Tipranavir/ritonavir (500/200 mg BID) demonstrated potent and durable virologic responses, and a favourable safety profile, in HIV-1 positive women participating in RESIST - (08/09/06)   A Randomized Comparative Trial of First-line Antiretroviral Therapy with Regimens Containing Either Nevirapine, or Efavirenz, Together with Stavudine and Lamivudine. Three-Year Extended Follow-Up of the 2NN Study. - (08/09/06)   EZETIMIBE COMBINED WITH LOW DOSE STATIN EFFECTIVELY LOWERS LDL IN PROTEASE INHIBITOR TREATED PATIENTS; Kaletra PK - (08/09/06)   Less than 95% adherence to ritonavir-boosted protease inhibitors leads to viral suppression: an update to address currently prescribed antiretroviral regimens - (08/09/06)   Sydney AIDS Conference: Scientific Advances Undercut by Rights Abuses - (08/08/06)   Global AIDS conference kicks off in Australia: Stop talking about cure for AIDS says Fauci - (08/08/06)   HIV/AIDS conference opens in Sydney - (08/08/06)   HIV-Drug Tenofovir Tested on Virus-Free People for Prevention PreP - (08/08/06)   Aussie mum tells of life with HIV at Sydney Conference Opening Session - (08/08/06)   International Experts and Women Living With HIV Discuss Urgent Needs of HIV-Positive Women at International AIDS Society (IAS) Congress - (08/08/06)   Aussie Govt promises $400m to fight HIV - (08/08/06)   Efficacy and safety of switching from boosted Lopinavir (LPV/r) to boosted Atazanavir (ATV/r) in patients with virologic suppression receiving a LPV/r containing HAART: The ATAZIP study - (08/08/06)   HIV Viral Tropism in Vicriviroc VICTOR-E1 Trial: Correlations With Clinical Variables - (08/08/06)   Safety of Vicriviroc in ARt-Experienced Subjects: 12-Week VICTOR-E1 Results With Updated 24-Week Data - (08/08/06)   Pharmacokinetics of multiple-dose darunavir in combination with low-dose ritonavir in individuals with impaired hepatic function - (08/08/06)   Effect of baseline and on-treatment mutations on the antiretroviral activity of darunavir/ritonavir and lopinavir/ritonavir: results of a randomised, controlled, Phase III study (TITAN) - (08/08/06)   Single-agent Therapy with Lopinavir/ritonavir Suppresses Plasma HIV-1 Viral Replication in HIV-1 Naive Subjects: IMANI-2 48-Week Results - (08/03/06)   LPV/r-based 2-drug HAART vs LPV/r-based 3-drug HAART: Comparable virological efficacy and tolerability in HIV-1-infected naive subjects (Kalead1 study) Ð 48-Week results - (08/03/06)   Lower prevalence of small, dense low-density lipoprotein (sd-LDL) in hypertriglyceridemic HIV-infected patients than in non-HIV-infected subjects - (08/03/06)   Treatment Breaks Boosted Bacterial Pneumonia Risk in SMART Trial - Written by Mark Mascolini - - (08/02/06)   Starting ART at Higher CD4 Count Lowers Nucleoside Toxicity Risk - Written by Mark Mascolini - - (08/02/06)   Evidence of international transmission of HCV in pan-European study of HIV-positive men who have sex with men (MSM) - (08/02/06)   A randomized study of tenofovir containing HAART compared to lamivudine containing HAART in antiretroviral naive HIV/HBV coinfected patients in Thailand: 48 week findings - (08/02/06)   HCV/HBV Coinfected at Greater Risk in SMART - (08/01/06)   Higher rate of HAART reinitiation among HIV-HBV coinfected patients in the episodic arm of the SMART study - (08/01/06)   Clash over drug access at Australia AIDS/HIV conference - (08/02/06)   New Data Suggest Boosted Invirase Has Similar Efficacy to Boosted Lopinavir in HIV Patients at 24 Weeks, Press Release from Roche - Written by Mark Mascolini - - (08/01/06)   Saquinavir/r bid vs Kaletra bid Efficacy Analysis 24 Weeks Gemini Study - (08/01/06)   Saquinavir/r bid vs Kaletra bid GEMINI Study, 24 weeks Interim Lipids Analysis - (08/01/06)   Twice-Daily Maraviroc Compared to Efavirenz in Treatment Naive - (08/01/06)   Determination of Body Composition Changes by Total Body Dual-Energy X-ray Absorptiometry after 48 Weeks of Treatment with Once-Daily Fosamprenavir (FPV) Boosted with Two Different Doses of Ritonavir(r) plus Abacavir(ABC)/ Lamivudine(3TC): COL100758 - (08/01/06)   Randomized Trials Results Back Gene Screening for Abacavir Reaction: PREDICT 1 and SHAPE - Written by Mark Mascolini - (07/31/06)   RESPONSE TO DARUNAVIR/RITONAVIR (DRV/R) COMBINED WITH ENFUVIRTIDE (ENF)-CONTAINING ARV IN TRIPLE-CLASS EXPERIENCED PATIENTS WAS NOT PREDICTED BY BASELINE DARUNAVIR (DRV) SENSITIVITY OR VIRAL TROPISM (VT): THE BLQ STUDY PRELIMINARY RESULTS - (07/31/06)   Six Year Safety and Efficacy of Tenofovir DF (TDF) in Combination with Lamivudine (3TC) and Efavirenz (EFV) in Antiretroviral-Naive Patients - (07/31/06)   Fuzeon Improved Maraviroc Response in MOTIVATE and Genotypic Sensitivity Score Matters - (07/31/06)   Efficacy and Safety of Once-Daily (QD) Compared with Twice-Daily (BID) Maraviroc plus Optimized Background Therapy (OBT) in treatment-experienced Patients Infected with CCR5-tropic HIV-1: 24-week Combined Analysis of the MOTIVATE 1 & 2 Studies - (07/31/06)   Fosamprenavir/r QD v Reyataz/r ALERT Study 48 Weeks - (07/31/06)   Three-year Safety and Efficacy of Emtricitabine (FTC)/Tenofovir DF (TDF) and Efavirenz (EFV) Compared to Fixed Dose Zidovudine/Lamivudine (AZT/3TC) and EFV in Antiretroviral Treatment-Naive Patients - (07/31/06)   Randomized Trials Results Back Gene Screening for Abacavir Reaction: PREDICT 1 and SHAPE Studies - Written by Mark Mascolini - (07/30/06)   ABC107442 (SHAPE) Study of Hypersensitivity to Abacavir and Pharmacogenetic Evaluation - (07/30/06)   Efficacy and safety of NRTI's switch to tenofovir plus emtricitabine (Truvada) vs. abacavir plus lamivudine (Kivexa) in patients with virologic suppression receiving a lamivudine containing HAART: The BICOMBO study - (07/30/06)   Phase II Study of the Safety and Efficacy of New CCR5 Drug Vicriviroc (VCV) in HIV+ Treatment-Experienced Subjects: 48-week Results - ACTG 5211 - (07/30/06)   Changes in Lipid Parameters During Treatment with Lopinavir/ritonavir (LPV/r) Plus Zidovudine/lamivudine (ZDV/3TC) Induction Followed by Maintenance on LPV/r Monotherapy Compared to Efavirenz (EFV) + ZDV/3TC Through 96 Weeks - (07/30/06)   No Change in Glucose Tolerance with Lopinavir/ritonavir (LPV/r)+ ZDV/3TC Induction Followed by LPV/r Monotherapy Through 96 Weeks - (07/30/06)   Treatment Simplification to an Atazanavir-Containing Regimen: Impact on Patients' Perception of Symptom Severity - (07/30/06)   Six Factors Predict Kidney Problems in French HIV Cohort - Written by Mark Mascolini - (07/27/06)   Giving Efavirenz With Rifampin Does Not Hurt 3-Year HIV/TB Outcome - Written by Mark Mascolini - (07/27/06)   Bristol-Myers Squibb's "SECURE THE FUTURE" Program Offers New Approach To Replicate Successful HIV Treatment Support Model - (07/27/06)   Push for early HAART treatment - (07/27/06)   Medical "brain drain" hindering AIDS battle; Lack of Medical Infrastructure in Developing Countries - (07/27/06)   HIV no longer a death sentence, Sydney conference told - (07/27/06)   Atazanavir modestly increases plasma levels of MK-0518 - (07/27/06)   Once-Daily CCR5 Antagonist Has Highly Sustained Effect - Written by Mark Mascolini - (07/27/06)   Likely Resistance to Etravirine Possibly Under 2% in French Cohort - Written by Mark Mascolini - (07/27/06)   Integrase Inhibitor Troughs One Third Lower With NNRTI Etravirine - Written by Mark Mascolini - (07/27/06)   Hints on Integrase Inhibitor Cross-Resistance From Two Case Studies - Written by Mark Mascolini - (07/27/06)   RNA Response, Coreceptor Swaps, and Cancers After 48 Weeks of Vicriviroc - Written by Mark Mascolini - (07/27/06)   Better Lipid Scores With TMC278 Than With Efavirenz - Written by Mark Mascolini - (07/27/06)   Once-Daily CCR5 Antagonist Has Highly Sustained Effect - Written by Mark Mascolini - (07/27/06)   Smoking Raises Death Risk--and Lung Disease Common--With HIV - Written by Mark Mascolini - (07/27/06)   Integrase Inhibitor Matches Efavirenz for 48 Weeks in Treatment-Naive - Written by Mark Mascolini - (07/27/06)   Raltegravir 48-week Naives potent; No Lipids Elevations - (07/27/06)   The metabolic profile of TMC278, an investigational NNRTI - (07/27/06)   Short-term monotherapy with UK-453,061, a novel NNRTI, reduces viral load in HIV-infected patients - (07/27/06)   Integrase Inhibitor Matches Efavirenz for 48 Weeks in Treatment-Naive - Written By Mark Mascolini - (07/26/06)   Brain disorders likely in HIV patients in Developing Asian Countries - (07/26/06)   Microbicide Viva Gel could stop HIV and herpes - (07/26/06)   New Incyte CCR5 Drug Shows Good Activity: 14 day monotherapy study - (07/26/06)   Efficacy and Safety of Atazanavir-Based Therapy in Antiretroviral-Naive HIV-1-Infected Subjects, Both With and Without Ritonavir: 96-Week Results From AI424-089 - (07/26/06)   Darunavir and Lopinavir Resistance Differences in TITAN - Written By Mark Mascolini - (07/26/06)   Comparison of 48-week efficacy and safety of darunavir/ritonavir (DRV/r) with lopinavir/ritonavir (LPV/r) in LPV/r-naive, treatment-experienced, patients: a randomised, controlled Phase III trial (TITAN) - (07/26/06)   A Multicenter, Randomized, Double-Blind, Comparative Trial of a Novel CCR5 Antagonist, Maraviroc Versus Efavirenz, both in Combination with Combivir (Zidovudine/Lamivudine), for the Treatment of Antiretroviral-Naive Subjects Infected with R5 HIV 1: Week 48 Results of the MERIT Study - (07/26/06)   Randomized Trial Results Back Gene Screening for Abacavir Reaction - Written By Mark Mascolini - (07/26/06)   MARAVIROC REDUCES HIV VIRAL LOAD IN TREATMENT-NAIVE PATIENTS, 48 WEEK DATA SHOW: Pfizer Press Release - (07/26/06)   DUET-1 and DUET-2: TMC125 versus placebo in treatment-experienced HIV-1-infected patients - (07/26/06)   Immediate Antiretrovirals Cut Death Risk by 76% in Infected Infants in South Africa Study - Written By Mark Mascolini - (07/26/06)   Slight Advantage Possible With Switch to Truvada vs Kivexa - Written By Mark Mascolini - (07/26/06)   Two Trials Find Lower Atherosclerosis Risk With Antiretrovirals - Written By Mark Mascolini - (07/26/06)   Post-sex washing 'doesn't lower HIV' - (07/26/06)   'HIV eradication now possible' - (07/20/06)   Significant rise in HIV in Australia: study - (07/20/06)   One in 350 patients is HIV-positive and they don't even know it in Singapore - (07/19/06)   Journalists flood Australia for AIDS conference - (07/19/06)   Report Card on Global AIDS Treatment Access Disappointments; MISSING THE TARGET #4: - (07/19/06)   New Report Critical of Global HIV Treatment Access: Zackie Achmat and Other Global AIDS Activist Leaders Release New Report on AIDS Treatment Scale Up - (07/19/06)   World struggling to treat HIV-AIDS - report - (07/19/06)